Archives: Speakers

Daniele Piccarozzi manages Sovereign AI & HPC initiatives for AMD across the EMEA region, driving strategy and ecosystem development for large-scale AI and high-performance computing programs. With extensive experience spanning both technical and commercial leadership, Daniele has contributed to the deployment of major HPC systems across Europe for scientific research and industrial applications, while working closely with governments, research institutions, OEMs and technology partners. Prior to AMD, he managed the HPC business at Arm and previously worked at IBM in technical and commercial roles focused on HPC and enterprise infrastructure.

Pharmaceutical physician and MHRA-accredited First in Human Principal Investigator with extensive experience leading First-in-Human and early clinical development studies across a broad range of modalities including siRNA therapeutics, monoclonal antibodies, immunology, inflammation, metabolic disease and novel translational medicine programs.

Currently Medical Director at Parexel’s Phase I Clinical Research Unit in London, with responsibility for medical oversight of complex early phase studies including study design, dose escalation, safety governance, PK/PD interpretation, protocol leadership, regulatory interaction and cross-functional collaboration with sponsor clinical pharmacology and translational medicine teams.

Experienced in the conduct of over 100 Phase I studies, including multiple RNA therapeutic programs and complex biomarker-driven translational studies. Particular interests include early clinical development strategy, translational medicine, biomarker integration, exposure-response relationships and novel modality development.

Board Certification (CCT) in Pharmaceutical Medicine (2023). Executive MBA.